How the site of cancer spread affects immune response in pancreatic cancer
Official title: The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity
Funded at Washington University · NIH-10931531 · Data updated 2026-11-12
This study is looking at how the location of pancreatic cancer spreads affects the body's immune response, with the goal of finding better ways to use immune cells to fight the cancer and help patients with advanced disease.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $612,272 |
| NIH project number | 5U01CA284086-02 |
| Project ID | NIH-10931531 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic pancreatic ductal adenocarcinoma.
✕Less likely to help
Patients with early-stage pancreatic cancer or those without metastatic disease may not benefit from this research.
What this research studies
This research investigates how the location of metastatic pancreatic cancer influences the immune response driven by dendritic cells. It aims to understand the differences in the tumor microenvironment between primary and metastatic sites, which may hinder effective immunotherapy. By studying both animal models and human samples, the research seeks to identify how these immune cells can be better utilized to enhance anti-tumor immunity. The findings could lead to improved strategies for treating patients with advanced pancreatic cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with metastatic pancreatic cancer.
How similar studies have gone: Previous research has shown that understanding the immune environment in cancer can lead to breakthroughs in treatment, suggesting this approach has potential for success.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Denardo, David G — Washington University
- Study coordinator: Denardo, David G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.